CY1108647T1 - Πολυμορφικες μορφες ενος αγωνιστη gabaa - Google Patents

Πολυμορφικες μορφες ενος αγωνιστη gabaa

Info

Publication number
CY1108647T1
CY1108647T1 CY20081101439T CY081101439T CY1108647T1 CY 1108647 T1 CY1108647 T1 CY 1108647T1 CY 20081101439 T CY20081101439 T CY 20081101439T CY 081101439 T CY081101439 T CY 081101439T CY 1108647 T1 CY1108647 T1 CY 1108647T1
Authority
CY
Cyprus
Prior art keywords
gabaa
agent
polymorphic forms
forms
new crystalline
Prior art date
Application number
CY20081101439T
Other languages
English (en)
Inventor
Vincent Brett Cooper
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108647(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1108647T1 publication Critical patent/CY1108647T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Δύο νέες κρυσταλλικές μονοένυδρες μορφές και δύο νέες κρυσταλλικές άνυδρες μορφές της γαμποξαδόλης αποκαλύπτονται μαζί με τις μεθόδους για την παρασκεύη τους.
CY20081101439T 2004-01-30 2008-12-10 Πολυμορφικες μορφες ενος αγωνιστη gabaa CY1108647T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
EP05702040A EP1713813B1 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (1)

Publication Number Publication Date
CY1108647T1 true CY1108647T1 (el) 2014-04-09

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101439T CY1108647T1 (el) 2004-01-30 2008-12-10 Πολυμορφικες μορφες ενος αγωνιστη gabaa

Country Status (35)

Country Link
US (2) US7262300B2 (el)
EP (2) EP2042505A1 (el)
JP (1) JP4917440B2 (el)
KR (1) KR101210361B1 (el)
CN (1) CN1914212B (el)
AR (1) AR047511A1 (el)
AT (1) ATE414088T1 (el)
AU (1) AU2005209473B2 (el)
BR (1) BRPI0506858A (el)
CA (1) CA2554536C (el)
CO (1) CO5700743A2 (el)
CY (1) CY1108647T1 (el)
DE (1) DE602005010975D1 (el)
DK (1) DK1713813T3 (el)
DO (1) DOP2005000013A (el)
EA (1) EA009413B1 (el)
EC (1) ECSP066735A (el)
ES (1) ES2314613T3 (el)
GB (2) GB0402118D0 (el)
HK (1) HK1096547A1 (el)
HR (1) HRP20080614T3 (el)
IL (1) IL176863A0 (el)
MA (1) MA28364A1 (el)
MX (1) MXPA06008595A (el)
MY (1) MY139525A (el)
NO (1) NO20063843L (el)
NZ (1) NZ548191A (el)
PE (1) PE20050769A1 (el)
PL (1) PL1713813T3 (el)
PT (1) PT1713813E (el)
SI (1) SI1713813T1 (el)
TW (1) TWI345972B (el)
UA (1) UA87487C2 (el)
WO (1) WO2005073237A2 (el)
ZA (1) ZA200605307B (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
ES2524994T3 (es) 2005-09-28 2014-12-16 Auris Medical Ag Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
MX2018000745A (es) * 2015-07-17 2018-08-15 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
CA3032686A1 (en) * 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Use of ganaxolone for treating status epilepticus in a subject
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
KR20210110585A (ko) 2018-11-21 2021-09-08 썰테고 테라퓨틱스 아이엔씨. 자살의 위험을 감소시키고 우울증의 신속한 완화를 위한 가복사돌
US11690829B2 (en) 2018-12-17 2023-07-04 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
CA3182508A1 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) * 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
WO2001022941A1 (en) 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
DE50205794D1 (de) 2001-05-18 2006-04-20 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
WO2002094225A1 (en) 2001-05-21 2002-11-28 H. Lundbeck A/S Granular preparations of gaboxadol
AU2002333157A1 (en) * 2002-09-03 2004-03-29 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
PT1641456E (pt) * 2003-06-25 2010-06-01 Lundbeck & Co As H Gaboxadol para o tratamento de depressão e outros distúrbios afectivos
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2008504306A (ja) 2004-06-29 2008-02-14 ハー・ルンドベック・アクチエゼルスカベット 神経因性疼痛、線維筋痛症または慢性関節リウマチの治療
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
WO2006083682A2 (en) 2005-01-28 2006-08-10 H.Lundbeck A/S Polymorphic forms of a gabaa agonist
EP1863808A1 (en) 2005-03-18 2007-12-12 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
EP1906953A4 (en) 2005-04-29 2009-05-20 Lundbeck & Co As H FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL

Also Published As

Publication number Publication date
US20070259912A1 (en) 2007-11-08
CA2554536C (en) 2012-09-18
CO5700743A2 (es) 2006-11-30
MXPA06008595A (es) 2006-08-28
JP2007519697A (ja) 2007-07-19
AR047511A1 (es) 2006-01-25
US20050171142A1 (en) 2005-08-04
IL176863A0 (en) 2006-10-31
GB2410434A (en) 2005-08-03
DK1713813T3 (da) 2009-02-16
TW200534856A (en) 2005-11-01
EP1713813A2 (en) 2006-10-25
WO2005073237A2 (en) 2005-08-11
HK1096547A1 (en) 2007-06-01
PE20050769A1 (es) 2005-10-04
NO20063843L (no) 2006-08-29
ECSP066735A (es) 2006-10-31
BRPI0506858A (pt) 2007-05-29
PT1713813E (pt) 2008-12-26
CN1914212A (zh) 2007-02-14
TWI345972B (en) 2011-08-01
NZ548191A (en) 2010-04-30
KR101210361B1 (ko) 2012-12-10
HRP20080614T3 (en) 2009-01-31
DE602005010975D1 (de) 2008-12-24
UA87487C2 (ru) 2009-07-27
WO2005073237A3 (en) 2005-10-20
EA200601404A1 (ru) 2006-12-29
MY139525A (en) 2009-10-30
AU2005209473B2 (en) 2010-03-04
PL1713813T3 (pl) 2009-04-30
EP1713813B1 (en) 2008-11-12
DOP2005000013A (es) 2005-08-15
US8236958B2 (en) 2012-08-07
ZA200605307B (en) 2007-11-28
JP4917440B2 (ja) 2012-04-18
SI1713813T1 (sl) 2009-02-28
MA28364A1 (fr) 2006-12-01
AU2005209473A1 (en) 2005-08-11
GB0402118D0 (en) 2004-03-03
EA009413B1 (ru) 2007-12-28
ES2314613T3 (es) 2009-03-16
CN1914212B (zh) 2010-10-06
US7262300B2 (en) 2007-08-28
ATE414088T1 (de) 2008-11-15
EP2042505A1 (en) 2009-04-01
KR20070007070A (ko) 2007-01-12
CA2554536A1 (en) 2005-08-11
GB0501847D0 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
CY1108647T1 (el) Πολυμορφικες μορφες ενος αγωνιστη gabaa
CY2016045I2 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
FR20C1027I2 (fr) Derives de tiglien-3-one
UY32049A (es) Inhibidores de cmet
CY1116339T1 (el) Πολυμορφικες μορφες ενος μακροκυκλικου αναστολεα hcv
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
ECSP10010246A (es) Inhibidores de beta-lactamasa
MA28347A1 (fr) Dérivés de quinoléine substitués
NO20081245L (no) Gruppeantenne og fremgangsmåte for måling mens det bores
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR10562A (es) Nuevos derivados de piridazina
DK1849488T3 (da) Kirurgisk kassette med eftergivende klemmezone
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
DK1735623T3 (da) Test til diagnosticering af infektion med mycobakterium tuberculosis
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DOP2006000261A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
ECSP088151A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
ITMI20052008A1 (it) Nuovi antimalarici derivati della 4-aminochinolina
ECSP088251A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
FR2934266B1 (fr) Derives azotes de la pancratistatine